Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

NCT ID: NCT02172495

Last Updated: 2018-08-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Symptoms of COPD

Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms

Tiotropium bromide

Intervention Type DRUG

Tiotropium bromide 18 micrograms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tiotropium bromide

Tiotropium bromide 18 micrograms

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Spiriva®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged at least 40 years with the symptoms of Chronic Obstructive Pulmonary Disease

Exclusion Criteria

* Patients with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

205.278

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Spiriva® Assessment of FEV1 (SAFE)
NCT00277264 COMPLETED PHASE3
SPIRIVA in Ususal Care
NCT00274079 COMPLETED PHASE4
Tiotropium (Spiriva) Rehabilitation Study
NCT00274521 COMPLETED PHASE3